Optimizing Timing for Respiratory Syncytial Virus Prevention Interventions for Infants.

ABSTRACT:

Importance

The Advisory Committee on Immunization Practices and the Centers for Disease Control and Prevention recommend seasonal administration of maternal vaccine (MV) or nirsevimab to protect infants in the first year of life from respiratory syncytial virus (RSV) infections. Differences in uptake, costs, and efficacy between these agents may affect cost-effectiveness depending on the timing of administration.

Objective

To evaluate the clinical outcomes and cost-effectiveness of no intervention, MV, and nirsevimab administration during the entire RSV season and separately for each monthly birth cohort from October through February.

Design, setting, and participants

This economic evaluation used a Markov model to analyze cost-effectiveness from a societal perspectiv

SUBMITTER: Nguyen D 

PROVIDER: S-EPMC12287852 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature